Management of Bleeding Events Associated with Venlafaxine

Understanding the Risk of Bleeding

Petechiae represent a form of abnormal bleeding that can be an early warning sign of more serious bleeding complications, according to the American Academy of Clinical Infectious Diseases 1
Review of complete blood count and coagulation studies is necessary to rule out other causes of bleeding, as recommended by the American Heart Association, with a strength of evidence based on observational studies 2

Discontinuation of venlafaxine with a slow taper is recommended to avoid withdrawal symptoms, as suggested by the American Academy of Child and Adolescent Psychiatry, with a moderate strength of evidence based on clinical trials 3
Consideration of alternative antidepressants with lower bleeding risk, such as certain SSRIs, is advised by the Mayo Clinic, with a high strength of evidence based on meta-analyses 4

Switching to an antidepressant with lower bleeding risk, such as certain SSRIs or other classes of antidepressants, is recommended by the Mayo Clinic, with a moderate strength of evidence based on observational studies 4
For patients with anxiety or neuropathic pain, pregabalin or gabapentin may be alternatives with less risk of bleeding, as suggested by the American Society of Clinical Oncology, with a low strength of evidence based on case reports 5

Tapering of venlafaxine rather than abrupt discontinuation is necessary to prevent withdrawal syndrome, as recommended by the American Academy of Child and Adolescent Psychiatry, with a high strength of evidence based on clinical trials 3
Individualization of the taper schedule based on dose, duration of treatment, and patient response is advised by the Mayo Clinic, with a moderate strength of evidence based on expert opinion 4